| 📌 The essentials On March 25, 2026, the FDA granted accelerated approval for AVLAYAH (tividenofusp alfa-eknm, Denali Therapeutics) for the treatment of neurologic manifestations of Hunter syndrome (mucopolysaccharidosis type II, MPS II) in pediatric patients weighing at least 5 kg, when initiated prior to advanced neurologic impairment. This is the first FDA-approved therapy specifically designed to cross the blood-brain barrier, and the first new FDA-approved treatment for Hunter syndrome in nearly 20 years. The clinical basis: Phase 1/2 trial (NCT02055118) in 47 patients (ages 0.3 to 13 years, median age 5), showing 91% reduction in CSF heparan sulfate (95% CI: 89% to 92%) by week 24, with 93% of treated patients (41 of 44) reaching CSF HS levels within the range of unaffected individuals. Secondary endpoints included improvements in Vineland-3 adaptive behavior scores, Bayley Scales of Infant and Toddler Development (BSID-III), liver volume normalization, and hearing. Accelerated approval context: continued approval may be contingent on the ongoing Phase 2/3 COMPASS confirmatory trial, which randomizes patients 2:1 to AVLAYAH versus idursulfase (standard of care) over 96 weeks. A Rare Pediatric Disease Priority Review Voucher was granted alongside the approval. |
|---|
When the National MPS Society shared news of the AVLAYAH approval on social media, the comments section filled with responses from parents who had been tracking this program for years. “We’ve been waiting 18 years for this.” That context is worth keeping in mind as we go through what this approval actually means, and what it does not yet answer.
AVLAYAH (tividenofusp alfa-eknm), developed by Denali Therapeutics, received FDA accelerated approval on March 25, 2026, as a treatment for Hunter syndrome (MPS II). It is the first new therapy for this condition in nearly two decades. It is also the first therapy ever designed to reach the brain.
What Is Hunter Syndrome?
Hunter syndrome (MPS II) is a rare, X-linked lysosomal storage disorder caused by a deficiency of the enzyme iduronate 2-sulfatase (IDS). Without sufficient IDS, complex sugars called glycosaminoglycans (GAGs), specifically heparan sulfate and dermatan sulfate, accumulate in cells throughout the body.
The condition is estimated to affect fewer than 500 people in the United States, almost all of them male. The consequences compound over time: developmental delays, cognitive regression, hearing loss, progressive joint stiffness, and organ dysfunction. The disease has a neuronopathic form, where the accumulation affects the brain and causes progressive neurological deterioration, and a non-neuronopathic form with primarily somatic (body) manifestations.
The existing treatment, Elaprase (idursulfase, Takeda), was approved in 2006. It has been the only FDA-approved therapy for Hunter syndrome for nearly 20 years. It reduces GAG accumulation in peripheral tissues and improves some physical symptoms, but it does not meaningfully cross the blood-brain barrier. Families managing the neuronopathic form have watched their children lose cognitive and developmental ground knowing that existing enzyme replacement therapy simply could not reach where the damage was happening.
What AVLAYAH Does Differently: The Blood-Brain Barrier Problem
The blood-brain barrier (BBB) is a highly selective physical barrier formed by the specialized endothelial cells lining brain capillaries. It protects the central nervous system from pathogens and toxins but also blocks the passage of most large molecules, including therapeutic proteins. Most enzyme replacement therapies, regardless of how effective they are in peripheral tissues, cannot reach the brain in therapeutic concentrations.
Denali’s approach to this problem is their TransportVehicle (TV) platform, which engineers therapeutic molecules to exploit a transport system the brain’s own blood vessels already use. The transferrin receptor (TfR1) is expressed on brain endothelial cells and mediates the transport of iron-bound transferrin across the BBB through receptor-mediated transcytosis. By engineering a therapeutic molecule to bind TfR1 with carefully tuned affinity, Denali can hitch the molecule across the BBB using this existing transport pathway.
Tividenofusp alfa consists of the IDS enzyme fused to an antibody fragment targeting TfR1. After intravenous infusion, the molecule circulates through the bloodstream, reaches brain blood vessels, binds to TfR1 on those vessels, and is transported into the brain, where the enzyme can then begin reducing the heparan sulfate accumulation that drives neurological deterioration. The same molecule also distributes to peripheral tissues, addressing the somatic manifestations of the disease through a standard intravenous infusion route, without requiring intrathecal (spinal) administration.
No spinal tap required. That is not a minor practical detail for pediatric patients and their families.
The Phase 1/2 Trial: What the Data Shows
The FDA accelerated approval is based on data from a Phase 1/2 international, multicenter, open-label trial (NCT02055118) published in the New England Journal of Medicine on January 1, 2026. The trial enrolled 47 patients with Hunter syndrome, including both enzyme replacement therapy-naive patients (n=15) and previously treated patients (n=32). Ages ranged from 0.3 to 13 years, with a median age of 5.
The primary objective was safety and tolerability. Secondary objectives evaluated CNS and peripheral effects through multiple biomarker and clinical measures.
| Endpoint | Result | Detail |
|---|---|---|
| CSF heparan sulfate reduction at week 24 | 91% reduction from baseline | 95% CI: 89% to 92% |
| Patients reaching normal CSF HS range at week 24 | 93% (41 of 44 evaluable) | Levels within range of individuals without Hunter syndrome |
| Vineland-3 adaptive behavior | Improvements observed | Measures real-world functional skills: communication, daily living, socialization |
| BSID-III developmental scales | Improvements observed | Bayley Scales of Infant and Toddler Development |
| Liver volume | Normalization observed | Hepatomegaly is a characteristic feature of MPS II |
| Hearing | Improvements observed | Hearing loss is a common complication of MPS II |
| Most common adverse reaction | Infusion-related reactions | Consistent with other enzyme replacement therapies |
Source: Denali Therapeutics FDA approval press release, March 25, 2026. New England Journal of Medicine. January 1, 2026. Phase 1/2 tividenofusp alfa in MPS II.
The 91% reduction in CSF heparan sulfate with 93% of patients reaching the normal range is a striking biomarker result for a rare disease study of this size. The secondary signals in adaptive behavior, developmental assessments, liver volume, and hearing add clinical texture to the biomarker data, suggesting the molecular effect is translating into meaningful functional signals across multiple organ systems.
Dr. Joseph Muenzer, MD, PhD, Director of the Muenzer MPS Research and Treatment Center and the Bryson Distinguished Professor in Pediatric Genetics at the University of North Carolina at Chapel Hill, described the approval as a breakthrough advance and the first therapeutic innovation for the Hunter syndrome community in nearly 20 years in a statement accompanying the approval announcement.
| What accelerated approval means here, and why the distinction matters Accelerated approval means the FDA accepted CSF heparan sulfate reduction as a surrogate endpoint reasonably likely to predict clinical benefit, a common pathway for rare diseases where full outcome trials would take years and withholding a promising therapy during that time carries its own cost. AVLAYAH still needs to demonstrate in the ongoing Phase 2/3 COMPASS study that reducing heparan sulfate actually slows or prevents cognitive decline at the clinical level. That is a meaningful distinction for families making treatment decisions right now: the biomarker effect is real and dramatic, but the evidence that it translates into preserved or improved cognitive and neurological function will come from the COMPASS study, not from the Phase 1/2 data. Continued approval may be contingent on those confirmatory trial results. |
|---|
The COMPASS Trial: What to Watch
The Phase 2/3 COMPASS confirmatory trial is the most important ongoing study in this program. It randomizes patients 2:1 to receive either AVLAYAH or idursulfase (the current standard of care, Elaprase), with a planned 96-week treatment duration. The trial is global and includes both pediatric and young adult participants with Hunter syndrome.
COMPASS is designed to do what the Phase 1/2 study could not: compare AVLAYAH to standard of care in a randomized, controlled design and assess whether the biomarker normalization translates into measurable clinical benefit in terms of cognitive and neurological function. The primary clinical endpoints will need to capture developmental trajectories over time, which is methodologically challenging in a disease with considerable individual variability.
The trial results are expected to take several years to mature fully. During that time, AVLAYAH is available for clinical use under the accelerated approval, and prescribing decisions will be made on the basis of the current Phase 1/2 biomarker and secondary data.
What We Still Do Not Know
Long-term cognitive outcomes
Biomarker normalization is the most encouraging early signal possible in a disease where the brain has historically been unreachable. Whether it translates into meaningfully preserved or improved cognitive trajectories over years will be answered by COMPASS. That answer will take time and will matter enormously for how this therapy is used and positioned.
Cost and access
Denali has not yet publicly announced U.S. list pricing. For ultra-rare disease therapies of this complexity, pricing will directly determine real-world access, especially for families navigating insurance coverage determinations or living outside the United States. The Rare Pediatric Disease Priority Review Voucher granted alongside the approval has significant commercial value for Denali and is a standard incentive mechanism created specifically to encourage development of therapies for conditions like Hunter syndrome, where market size alone does not support development investment. Denali Patient Services is available as a support resource; the practical details of coverage assistance will matter significantly for affected families.
Global regulatory submissions
COMPASS is designed to support global regulatory submissions beyond the U.S. Families outside the United States are watching those timelines closely.
Why This Matters Beyond Hunter Syndrome
The neuroscience community is watching this approval closely for reasons that extend beyond the MPS II patient population.
The blood-brain barrier has been one of the central unsolved problems in treating neurological diseases for decades. Most large molecules cannot get through it. Delivering enzyme replacement therapy, gene therapy vectors, antibody-based biologics, or any other large therapeutic molecule to the brain in meaningful concentrations has required either intrathecal delivery (spinal administration) or has simply not been possible at all for most candidates.
Denali’s TransportVehicle platform is now a clinically validated approach to crossing that barrier in humans, not just a promising hypothesis from animal models. The company has applied the same technology to other conditions, including Alzheimer’s disease-related programs targeting BACE1. This approval is the kind of proof-of-concept that tends to accelerate an entire field of drug development. If COMPASS confirms the clinical benefit and the platform continues to hold up in other applications, the implications extend well beyond lysosomal storage disorders to neurodegenerative disease more broadly.
For related coverage of other rare pediatric disease FDA approvals and the regulatory frameworks supporting them, see our posts on the first gene therapy for genetic deafness and what the Rare Pediatric Disease PRV means for rare disease development and the UX111 gene therapy BLA for Sanfilippo syndrome now under FDA review.
For Families and Clinicians
For patients with Hunter syndrome and their families, AVLAYAH represents the first treatment specifically designed to address the neurological aspect of the disease. The therapy is available in the United States under the accelerated approval. The label specifies initiation in presymptomatic or symptomatic patients prior to advanced neurologic impairment, which underscores the importance of early identification and newborn screening programs for MPS II.
Optimal management of Hunter syndrome is through a specialist in metabolic or lysosomal storage disorders, ideally at a center with MPS expertise. The National MPS Society provides disease information, family support, a physician directory, and real-time updates on treatment access and the AVLAYAH program. Project Alive focuses specifically on MPS II research and family support. The National Organization for Rare Disorders (NORD) maintains a clinical overview of MPS II with current treatment and research information.
Sources
FDA approval press announcement: FDA Approves Drug to Treat Neurologic Manifestations of Hunter Syndrome. FDA.gov. March 25, 2026.
Denali Therapeutics investor press release: Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II). GlobeNewswire. March 25, 2026.
Phase 1/2 trial primary publication: Phase 1/2 study of tividenofusp alfa in Hunter syndrome. New England Journal of Medicine. January 1, 2026.
Phase 1/2 trial registration: NCT02055118. ClinicalTrials.gov.
COMPASS trial search: COMPASS tividenofusp. ClinicalTrials.gov.
NeurologyLive clinical coverage: FDA Grants Accelerated Approval to Tividenofusp Alfa for Neurologic Hunter Syndrome. neurologylive.com. March 2026.
Child Neurology clinical commentary: FDA Grants Accelerated Approval to Tividenofusp Alfa for Neurologic Hunter Syndrome. child-neurology.org. March 2026.
PharmExec approval coverage: FDA Approves Avlayah for Treatment of Hunter Syndrome. pharmexec.com. 2026.
Elaprase (idursulfase) FDA approval: FDA approves idursulfase for Hunter syndrome. FDA.gov.
Blood-brain barrier overview: Blood-Brain Barrier. StatPearls. NCBI.
TfR1-mediated transcytosis: Transferrin Receptor as a Brain Drug Delivery Vehicle. PMC6558765.
MPS II/Hunter syndrome GARD: Mucopolysaccharidosis Type II. rarediseases.info.nih.gov.
IDS gene: IDS gene. NCBI.
Glycosaminoglycans biology: Glycosaminoglycans. StatPearls. NCBI.
Accelerated approval pathway: Accelerated Approval Program. FDA.gov.
Rare Pediatric Disease PRV: Rare Pediatric Disease Priority Review Voucher Program. FDA.gov.
Denali TV platform: Blood-Brain Barrier Science. denalitherapeutics.com.
Patient resources: National MPS Society | Project Alive | NORD: MPS II | ClinicalTrials.gov: COMPASS
| Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. AVLAYAH received accelerated approval; continued approval may be contingent on confirmatory trial results from the COMPASS study. Treatment decisions for Hunter syndrome should be made in consultation with a qualified specialist in metabolic or lysosomal storage disorders. |
|---|